Acesso livre
Acesso livre

Vacinas

EUA aprovam 2ª dose de reforço contra Covid-19 para pessoas de 50 anos de idade ou mais e indivíduos imunocomprometidos.

31 Mar, 2022 | 13:41h

U.S. approves second Covid-19 booster for people 50 and older – STAT

FDA OKs second COVID booster shot for older Americans – CIDRAP

Ver diretriz: Coronavirus (COVID-19) Update: FDA Authorizes Second Booster Dose of Two COVID-19 Vaccines for Older and Immunocompromised Individuals – U.S. Food & Drug Administration

Opinião | Vacinação global deve ser mais rápida.

29 Mar, 2022 | 15:14h

Global vaccination must be swifter – Nature

Moderna solicita que o FDA autorize o uso de sua vacina contra Covid-19 em crianças de 6 meses a 6 anos de idade.

29 Mar, 2022 | 14:19h

Moderna to ask FDA to authorize Covid-19 vaccine in children 6 months to 6 years – STAT

Coorte retrospectiva | Um estudo de base populacional feito na Suécia e na Noruega não encontrou um risco aumentado de complicações gestacionais após vacinação contra COVID-19.

29 Mar, 2022 | 14:15h

Association of SARS-CoV-2 Vaccination During Pregnancy With Pregnancy Outcomes – JAMA

Ver também: Association of COVID-19 Vaccination in Pregnancy With Adverse Peripartum Outcomes – JAMA

Editorial: COVID-19 mRNA Vaccines During Pregnancy: New Evidence to Help Address Vaccine Hesitancy – JAMA

Comunicado de imprensa: No increase in pregnancy complications after COVID-19 vaccination – Karolinska Institutet

[Preprint] Risco de morte após infecção pelo SARS-CoV-2 ou vacinação contra COVID-19 em jovens na Inglaterra.

25 Mar, 2022 | 15:59h

Risk of death following SARS-CoV-2 infection or COVID-19 vaccination in young people in England: a self-controlled case series study – medRxiv

 

Comentário no Twitter

 

Estudo randomizado | Segurança e eficácia da terceira dose de vacina da Pfizer contra Covid-19 durante a onda Delta.

25 Mar, 2022 | 14:56h

Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine – New England Journal of Medicine

 

Comentário no Twitter

 

Efetividade da vacina da Johnson & Johnson em profissionais da área da saúde na África do Sul no período em que as variantes de preocupação beta, e depois a delta, do SARS-CoV-2 eram dominantes.

22 Mar, 2022 | 11:52h

Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study – The Lancet

Comentário convidado: Sisonke: reaching several goals together – The Lancet

 

Comentário no Twitter (fio – clique para saber mais)

 

Miocardite após 3ª dose de vacina da Pfizer em recrutas militares em Israel.

22 Mar, 2022 | 11:49h

Myocarditis Following a Third BNT162b2 Vaccination Dose in Military Recruits in Israel – JAMA

Conteúdos relacionados:

Myocarditis following COVID-19 BNT162b2 vaccination among adolescents in Hong Kong.

[Preprint] Post-marketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12-39 years in Italy.

Myocarditis after BNT162b2 vaccination in Israeli adolescents.

Myocarditis cases reported after mRNA-Based COVID-19 vaccination in the US from December 2020 to August 2021.

A case-control study showed an increased risk of myocarditis after COVID-19 vaccination with a messenger RNA vaccine compared to an inactivated virus vaccine.

[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection.

Case series with 139 adolescents and young adults with suspected myocarditis following mRNA vaccination showed most cases had a mild clinical course and rapid resolution of symptoms.

Heart-inflammation risk from Pfizer COVID vaccine is very low.

Large cohort study with over 2.5 million individuals showed the incidence of myocarditis after the Pfizer vaccine was 2.13 cases per 100,000 persons.

Study with over 5.1 million vaccinated individuals showed the incidence of myocarditis after the receipt of the Pfizer vaccine was low and more common after the second dose in young male recipients.

Large Observational study shows Pfizer Covid vaccine is mostly safe but is associated with increased risk of myocarditis, adenopathy, appendicitis, and herpes zoster.

Estudo mostra que não há risco aumentado de eventos neurológicos raros após vacinação contra Covid.

21 Mar, 2022 | 16:31h

Comunicado de imprensa: Study finds no increased risk of rare neurological events after covid vaccination – BMJ Newsroom

Estudo original: Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis – The BMJ

Editorial: The neurological safety of covid-19 vaccines

Entre profissionais da área da saúde, a efetividade da 4ª dose de vacina contra infecção pela variante Ômicron do SARS-CoV-2 foi de 30% para a Pfizer–BioNTech e 11% para a Moderna.

17 Mar, 2022 | 13:19h

Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron – New England Journal of Medicine

Conteúdo relacionado: [Preprint] Fourth dose of COVID vaccine offers only slight boost against Omicron infection.

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.